A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes

Bibliography

• Stratton I, Adler AI, Neil HAW, Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
   PubMed Web of Science ®Google Scholar
• Hoerger TJ, Segel JE, Gregg EW, Saadine JB. US trends in glycemic control, treatment, and comorbidity burden in patients with diabetes. Diabetes Care 2008;31:81-6
   PubMed Web of Science ®Google Scholar
• Kahn SE, Haffner SM, Heise MA, ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43
   PubMed Web of Science ®Google Scholar
• Nicolucci A, Rossi MC. Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes. Acta Biomed 2008;79:184-91
   PubMedGoogle Scholar
• Frier BM How hypoglycaemia can affect the life of a person with diabetes. Diabetes Metab Res Rev 2008;24:8-92
   Web of Science ®Google Scholar
• Handelsman Y, Blonde L, Bloomgarden ZT, American Association of Clinical Endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract 2011;17(Suppl 2):S1-53
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, Management of hyperglycemia in type 2 diabetes: a patient-centred approach. Diabetes Care 2012;35:1364-79
   PubMed Web of Science ®Google Scholar
• Tzoulaki I, Molokhia M, Curcin V, Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009;339:b4731
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705
   PubMed Web of Science ®Google Scholar
• Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986;29:46-52
   PubMed Web of Science ®Google Scholar
• Vilsboll T, Krarup T, Sonne J, Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 2003;88:2706-13
   PubMed Web of Science ®Google Scholar
• Toft-Nielsen MB, Damholt MB, Madsbad S, Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001;86:3717-23
   PubMed Web of Science ®Google Scholar
• Bagger JI, Knop FK, Lund A, Impaired regulation of the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab 2011;96:737-45
   PubMed Web of Science ®Google Scholar
• Nauck MA, Vardarli I, Deacon CF, Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 2011;54:10-18
   PubMed Web of Science ®Google Scholar
• Kjems LL, Holst JJ, Volund A, Madsbad S. The influence of GLP-1 on glucose stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and non-diabetic subjects. Diabetes 2003;52:380-6
   PubMed Web of Science ®Google Scholar
• Nauck MA, Kleine N, Orskov C, Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:741-4
   PubMed Web of Science ®Google Scholar
• Meier JJ, Gallwitz B, Salmen S, Normalisation of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 2003;88:2719-25
   PubMed Web of Science ®Google Scholar
• Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-30
   PubMed Web of Science ®Google Scholar
• Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hyrolyses gastric inhibitory polypeptide, glucagon-like peptide 1 (7-39)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993;214:829-35
   PubMedGoogle Scholar
• Novo Nordisk Ltd. Victoza (liraglutide) summary of product characteristics. 2012. Available from: http://emc.medicines.org.uk/medicine/21986/SPC/Victoza+6+mg%2Fml+solution+for+injection+in+pre-filled+pen/ [Last accessed 14 March 2012]
   Google Scholar
• Amylin Pharmaceuticals/Eli Lilly. Byetta (exenatide) summary of product characteristics. 2009. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000698/WC500051845.pdf [Last accessed 14 March 2012]
   Google Scholar
• Eli Lilly and Co. Ltd. Bydureon summary of product characteristics. 2011. Available from: http://www.medicines.org.uk/EMC/medicine/24665/SPC/BYDUREON+2+mg+powder+and+solvent+for+prolonged-release+suspension+for+injection/ [Last accessed 14 March 2012]
   Google Scholar
• Fonseca VA, Alvarado-Ruiz R, Raccah D, on behalf of the EFC6018 GetGoal-Mono Study Investigators. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care 2012;35:1225-31
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Reusch J, Bush M, Albiglutide Study Group. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 2009;32:1880-6
   PubMed Web of Science ®Google Scholar
• Pratley RE, Nauck M, Bailey T, Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomized, parallel-group, open label trial. Lancet 2010;375:1447-56
   PubMed Web of Science ®Google Scholar
• Bergenstal RM, Wysham C, MacConell L, for the DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010;376:431-9
   PubMed Web of Science ®Google Scholar
• Russell-Jones D, Cuddihy RM, Hanefeld M, DURATION-4 Study Group. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 2012;35:252-8
   PubMed Web of Science ®Google Scholar
• Goke R, Fehmann HC, Linn T, Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 1993;268:19650-5
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Buse JB, Taylor K, Exenatide once-weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372:1240-50
   PubMed Web of Science ®Google Scholar
• Fineman M, Flanagan S, Taylor K, Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet 2011;50:65-74
   PubMed Web of Science ®Google Scholar
• DeYoung MB, MacConell L, Sarin V, Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther 2011;13:1145-54
   PubMed Web of Science ®Google Scholar
• Garber A, Henry R, Ratner R, LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-81
   PubMed Web of Science ®Google Scholar
• Nauck MA, Frid A, Hermansen K, LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes. Diabetes Care 2009;32:84-90
   PubMed Web of Science ®Google Scholar
• Marre M, Shaw J, Brandle M, LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1). Diabet Med 2009;26:268-78
   PubMed Web of Science ®Google Scholar
• Buse JB, Rosenstock J, Sesti G, LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47
   PubMed Web of Science ®Google Scholar
• Zinman B, Gerich J, Buse JB, LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4). Diabetes Care 2009;32:1224-30
   PubMed Web of Science ®Google Scholar
• Russell-Jones D, Vaag A, Schmitz O, on behalf of the LEAD-5 (Liraglutide Effect and Action in Diabetes 5) met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulphonylurea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD-5). Diabetologia 2009;52:2046-55
   PubMed Web of Science ®Google Scholar
• DeVries JH, Bain SC, Rodbard HW, on behalf of the Liraglutide-Detemir Study Group. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabetes Care 2012; doi:10.2337/DC11-1928.
   Web of Science ®Google Scholar
• Buse JB, Henry RR, Han J, Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Ratner RE, Han J, Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100
   PubMed Web of Science ®Google Scholar
• Kendall DM, Riddle MC, Rosenstock J, Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91
   PubMed Web of Science ®Google Scholar
• Moretto TJ, Milton DR, Ridge TD, Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008;30:1448-60. Erratum: 2008;30:1937
   PubMed Web of Science ®Google Scholar
• Zinman B, Hoogwerf BJ, Duran Garcia S, The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007;146:477-85
   PubMed Web of Science ®Google Scholar
• Buse JB, Bergenstal RM, Glass LC, Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011;154:103-12
   PubMed Web of Science ®Google Scholar
• Diamant M, Van Gaal L, Stranks S, Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010;375:2234-43
   PubMed Web of Science ®Google Scholar
• Blevins T, Pullman J, Malloy J, DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011;96:1301-10
   PubMed Web of Science ®Google Scholar
• Buse JB, Nauck MA, First T, Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): a randomised, open-label study [abstract 75]. Diabetologia 2011;54(Suppl 1):S38
   Google Scholar
• Garber A, Henry RR, Ratner R, LEAD-3 (Mono) Study Group. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab 2011;13:348-56
   PubMed Web of Science ®Google Scholar
• Ratner RE, Maggs D, Nielsen LL, Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 2006;8:419-28
   PubMed Web of Science ®Google Scholar
• Blonde L, Klein EJ, Han J, Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006;8:436-47
   PubMed Web of Science ®Google Scholar
• Taylor K, Gurney K, Han J, Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. BMC Endocr Disord 2011;11:9
   PubMed Web of Science ®Google Scholar
• Buse JB, Sesti G, Schmidt WE, Liraglutide Effect Action in Diabetes-6 Study Group. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care 2010;33:1300-3
   PubMed Web of Science ®Google Scholar
• Buse JB, Drucker DJ, Taylor KL, DURATION-1 Study Group. DURATION-1: exenatide once weekly produces sustained glycaemic control and weight loss over 52 weeks. Diabetes Care 2010;33:1255-61
   PubMed Web of Science ®Google Scholar
• Ryder REJ, Thong KY, Cull ML, The association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits [abstract 804]. Diabetologia 2011;54(Suppl 1):S326
   Google Scholar
• Agersø H, Jensen LB, Elbrønd B, The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002;45:195-202
   PubMed Web of Science ®Google Scholar
• Kolterman OG, Kimm DD, Shen L, Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005;62:173-81
   PubMed Web of Science ®Google Scholar
• Sturis J, Gotfredsen CF, Rømer J, GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol 2003;140:123-32
   PubMed Web of Science ®Google Scholar
• Rolin B, Larsen MO, Gotfredsen CF, The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002;283:E745-52
   PubMed Web of Science ®Google Scholar
• Best JH, Pelletier EM, Herman WH, Risk of cardiovascular events in patients with diabetes treated with exenatide or other glucose-lowering therapies; a retrospective analysis of the LifeLink™ Database [abstract 712-P]. Diabetes 2010;59(Suppl 1):A194
   Google Scholar
• Vilsbøll T, Christensen M, Junker AE, Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012;344:d7771
   PubMed Web of Science ®Google Scholar
• Fonseca V, Falahati A, Zychma M, Liraglutide, a once-daily human GLP-1 analogue, reduces systolic blood pressure within 2 weeks in patients with type 2 diabetes [poster D-0908]. IDF 2009 20th World Congress Abstract Book, IDF; Montreal, Canada, 2009. p. 310
   Google Scholar
• Plutzky J, Garber A, Toft AD, Poulter NR. Meta-analysis demonstrates that liraglutide, a once-daily human GLP-1 analogue, significantly reduces lipids and other markers of cardiovascular risk in type 2 diabetes [abstract 762]. Diabetologia 2009;52(Suppl 1):S299
   PubMedGoogle Scholar
• Russell-Jones D, Sesti G, Garber A, Liraglutide causes reductions in body weight both in patients with and without gastrointestinal side effects [abstract 1886-P]. Diabetes 2010;59(Suppl 1):A493
   Google Scholar
• Eli Lilly. DURATION-6 Top-Line Study Results Announced. 2011. Available from: https://investor.lilly.com/releasedetail2.cfm?ReleaseID=554248 [Last accessed 16 February 2012]
   Google Scholar
• Buse JB, Garber A, Rosenstock J, Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. J Clin Endocrinol Metab 2011;96:1695-702
   PubMed Web of Science ®Google Scholar
• Fineman MS, Mace KF, Diamant M, Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment Diabetes Obes Metab. 2012;14:546-54
   Google Scholar
• Simonsen L, Holst JJ, Deacon CF. Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetized pigs. Diabetologia 2006;49:706-12
   PubMed Web of Science ®Google Scholar
• Malm-Erjefalt M, Bjørnsdottir I, Vanggaard J, Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos 2010;38:1944-53
   PubMed Web of Science ®Google Scholar
• Davidson JA, Brett J, Falahati A, Scott D. Mild renal impairment has no effect on the efficacy and safety of liraglutide. Endocr Pract 2011;17:345-55
   PubMed Web of Science ®Google Scholar
• Flint A, Nazzal K, Jagielski P, Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide. Br J Clin Pharmacol 2010;70:807-14
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Information for Healthcare Professionals: Exenatide (marketed as Byetta) – 8/2008 Update. 2008. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm [Last accessed 14 March 2012]
   Google Scholar
• US Food and Drug Administration. Information for Healthcare Professionals – Acute pancreatitis and sitagliptin (marketed as Januvia and Janumet). 2009. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm183764.htm [Last accessed 14 March 2012]
   Google Scholar
• Elashoff M, Matveyenko AV, Gier B, Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011;141:150-6
   PubMed Web of Science ®Google Scholar
• Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010;33:2349-54
   PubMed Web of Science ®Google Scholar
• Pendergrass M, Chen W. Association between diabetes, exenatide, sitagliptin and acute pancreatitis. Diabetes 2010;59(Suppl 1):A160; 587-P
   Google Scholar
• Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009;25:1019-27
   PubMed Web of Science ®Google Scholar
• Wenten M, Gaebler J, Hussein M, A retrospective cohort study to assess the relative risk of acute pancreatitis among initiators of exenatide compared to initiators of other antidiabetic medication: a follow-up study. Diabetes 2010;59(Suppl 1):A163; 596-P
   Google Scholar
• Dore DD, Bloomgren GL, Wenten M, A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab 2011;13:559-66
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Victoza highlights of prescribing information. 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022341s004lbl.pdf [Last accessed 14 March 2012]
   Google Scholar
• Lee PH, Stockton MD, Franks AS. Acute pancreatitis associated with liraglutide. Ann Pharmacother 2011;45:e22
   Web of Science ®Google Scholar
• Knezevich E, Crnic T, Kershaw S, Drincic A. Liraglutide-associated acute pancreatitis. Am J Health Syst Pharm 2012;69:386-9
   PubMed Web of Science ®Google Scholar
• Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide – the FDA's review of a new antidiabetic therapy. N Engl J Med 2010;362:774-7
   PubMed Web of Science ®Google Scholar
• Bjerre Knudsen L, Madsen LW, Andersen S, Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010;151:1473-86
   PubMed Web of Science ®Google Scholar
• Hegedus L, Moses AC, Zdravkovic M, GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab 2011;96:853-60
   PubMed Web of Science ®Google Scholar
• Madsen LW, Knauf JA, Gotfredsen C, GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. Endocrinology 2012;153:1538-47
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Bydureon highlights of prescribing information. 2012. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022200s000lbl.pdf [Last accessed 27 March 2012]
   Google Scholar
• American Association of Clinical Endocrinologists. AACE Statement on liraglutide. 2010. Available from: https://www.aace.com/publications/online-news/March-16-2010 [Last accessed 27 February 2012]
   Google Scholar
• US Food and Drug Administration. Guidance for Industry: Diabetes Mellitus – Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat type 2 Diabetes. 2008. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf [Last accessed 27 February 2012]
   Google Scholar
• Marso SP, Lindsey JB, Stolker JM, Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase II: 3 liraglutide clinical development studies. Diab Vasc Dis Res 2011;8:237-40
   PubMed Web of Science ®Google Scholar
• Ratner R, Han J, Nicewarner D, Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol 2011;10:22
   PubMed Web of Science ®Google Scholar
• Linnebjerg H, Seger M, Kothare P, The effect of exenatide on QTc interval in healthy subjects [abstract 597-P]. Diabetes 2009;58(Suppl 1):A161
   Google Scholar
• Sager P, Darpo B, Han J, Exenatide once weekly did not affect corrected QT interval in patients with type 2 diabetes [abstract 1070-P]. Diabetes 2011;60(Suppl 1):A294
   Google Scholar
• Chatterjee DJ, Khutoryansky N, Zdravkovic M, Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes. J Clin Pharmacol 2009;11:1353-62
   Google Scholar
• Bergenstal R, Daniels G, Mann J, Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER™) trial: rationale and study design [abstract 2303-PO]. Diabetes 2011;59(Suppl 1):A612-13
   Google Scholar
• Bradley C. The diabetes treatment satisfaction questionnaire: DTSQ. In: Bradley C, editor. Handbook of psychology and diabetes: a guide to psychological measurement in diabetes research and practice. Harwood Academic Publishers; Chur, Switzerland: 1994
   Google Scholar
• Schmidt WE, Christiansen JS, Hammer M, Patient-reported outcomes are superior in patients with type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study. Diabet Med 2011;28:715-23
   PubMed Web of Science ®Google Scholar
• Best JH, Boye KS, Rubin RR, Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. Diabet Med 2009;26:722-8
   PubMed Web of Science ®Google Scholar
• Smith IC, Chubb B, Valentine W. Cost-effectiveness of liraglutide compared to exenatide in combination with metformin and/or sulphonylurea [poster 406]. Diabet Med 2010;27(Suppl 1):37-188
   PubMedGoogle Scholar
• Schlander M, Mentrup S, Lund N. Addition of incretin-therapy to metformin in type-2-diabetes mellitus (T2DM): cost-effectiveness of liraglutide versus sitagliptin from the perspective of the German Statutory Health Insurance (SHI). Value Health 2010;13:A291
   Web of Science ®Google Scholar
• Macconell L, Malloy J, Huang W, Safety and efficacy of once-monthly exenatide over 20 weeks in patients with type 2 diabetes [abstract 46-LB]. Presented at the American Diabetes Association 71st Scientific Sessions; 2011
   Google Scholar
• Luskey K, Rosenstock J, Alessi T, Henry RR. Long-term, injection-free treatment with ITCA 650, a continuous subcutaneous delivery of exenatide via DUROS® device, leads to stable glycaemic and weight control for 48 weeks in metformin-treated type 2 diabetes [abstract 77]. Diabetologia 2011;54(Suppl 1):S39
   Google Scholar
• Astrup A, Rossner S, Van Gaal L, NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009;374:1606-16
   PubMed Web of Science ®Google Scholar
• Astrup A, Carraro R, Finer N, Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2011; doi:10.1038/ijo.2011.158
   PubMed Web of Science ®Google Scholar
• Elkind-Hirsch K, Marrioneaux O, Bhushan M, Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008;93:2670-8
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Klaff LJ, Schwartz S, Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care 2010;33:1173-5
   PubMed Web of Science ®Google Scholar
• Kelly AS, Metzig AM, Rudser KD, Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study. Obesity (Silver Spring) 2012;20:364-70
   PubMed Web of Science ®Google Scholar
• Sze L, Purtell L, Jenkins A, Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome. J Clin Endocrinol Metab 2011;96:E1314-19
   PubMed Web of Science ®Google Scholar
• Raman VS, Mason KJ, Rodriguez LM, The role of adjunctive exenatide therapy in pediatric type 1 diabetes. Diabetes Care 2010;33:1294-6
   PubMed Web of Science ®Google Scholar
• Varanasi A, Bellini N, Rawal D, Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol 2011;165:77-84
   PubMed Web of Science ®Google Scholar
• Kielgast U, Krarup T, Holst JJ, Madsbad S. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care 2011;34:1463-8
   PubMed Web of Science ®Google Scholar
• Ghofaili KA, Fung M, Ao Z, Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes. Transplantation 2007;83:24-8
   PubMed Web of Science ®Google Scholar